Stocks and Investing
Stocks and Investing
Tue, April 30, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sumant Kulkarni Maintained (ANVS) at Strong Buy with Decreased Target to $26 on, Apr 30th, 2024
Sumant Kulkarni of Canaccord Genuity, Maintained "Annovis Bio, Inc." (ANVS) at Strong Buy with Decreased Target from $36 to $26 on, Apr 30th, 2024.
Sumant has made no other calls on ANVS in the last 4 months.
There is 1 other peer that has a rating on ANVS. Out of the 1 peers that are also analyzing ANVS, all agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tyler Bussian of "Brookline Capital" Downgraded from Strong Buy to Hold and Held Target at $9 on, Wednesday, February 28th, 2024
Contributing Sources